1
|
Barman TK, Kumar M, Chaira T, Singhal S, Mathur T, Kalia V, Gangadharan R, Rao M, Pandya M, Bhateja P, Sood R, Upadhyay DJ, Varughese S, Yadav A, Sharma L, Ramadass V, Kumar N, Sattigeri J, Bhatnagar PK, Raj VS. Novel fluorobenzothiazole as a dual inhibitor of gyrase B and topoisomerase IV against Gram-positive pathogens. Future Microbiol 2023; 18:625-638. [PMID: 37347211 DOI: 10.2217/fmb-2022-0207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/23/2023] Open
Abstract
Aim: The development of a novel inhibitor targeting gyrase B and topoisomerase IV offers an opportunity to combat multidrug resistance. Methods: We investigated the activity of RBx 10080758 against Gram-positive bacteria in vitro and in vivo. Results: RBx 10080758 showed a potent 50% inhibitory concentration of 0.13 μM and 0.25 μM against gyrase B and topoisomerase IV, respectively, and exhibited strong whole-cell in vitro activity with MIC ranges of 0.015-0.06 and 0.015-0.03 μg/ml against Staphylococcus aureus and Streptococcus pneumoniae, respectively. In a rat thigh infection model with methicillin-resistant S. aureus, RBx 10080758 at 45 mg/kg exhibited a >3 log10 CFU reduction in thigh muscles. Conclusion: RBx 10080758 displayed potent activity against multiple multidrug-resistant Gram-positive bacteria with a dual-targeting mechanism of action.
Collapse
Affiliation(s)
- Tarani K Barman
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Manoj Kumar
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
- Research Department, Sidra Medicine, Doha, 26999, Qatar
| | - Tridib Chaira
- Department of Metabolism & Pharmacokinetics, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Drug Metabolism & Pharmacokinetics, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
- Department of Pharmacology, SGT University, Gurugram, 122505, Haryana, India
| | - Smita Singhal
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Tarun Mathur
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Vandana Kalia
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Ramkumar Gangadharan
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
- Department of Pharmacology, SGT University, Gurugram, 122505, Haryana, India
| | - Madhvi Rao
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Manisha Pandya
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Pragya Bhateja
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Ruchi Sood
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Dilip J Upadhyay
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Shibu Varughese
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Ajay Yadav
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Lalima Sharma
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Venkataramanan Ramadass
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Naresh Kumar
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Jitendra Sattigeri
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - Pradip K Bhatnagar
- Department of Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Chemistry, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
| | - V Samuel Raj
- Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R & D III, Sector-18, Gurgaon, 122 015, India
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Gurgaon, 122 015, India
- Centre for Drug Design Discovery & Development (C4D), SRM University, Delhi-NCR, Sonepat, 131 029, Haryana, India
| |
Collapse
|
2
|
Nguyen TQ, Heo BE, Hanh BTB, Jeon S, Park Y, Choudhary A, Lee S, Kim TH, Moon C, Min SJ, Jang J. DS86760016, a Leucyl-tRNA Synthetase Inhibitor, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother 2023; 67:e0156722. [PMID: 37212672 PMCID: PMC10269085 DOI: 10.1128/aac.01567-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 04/27/2023] [Indexed: 05/23/2023] Open
Abstract
Benzoxaboroles are a new class of leucyl-tRNA synthetase inhibitors. Epetraborole, a benzoxaborole, is a clinical candidate developed for Gram-negative infections and has been confirmed to exhibit favorable activity against a well known pulmonary pathogen, Mycobacterium abscessus. However, according to ClinicalTrials.gov, in 2017, a clinical phase II study on the use of epetraborole to treat complicated urinary tract and intra-abdominal infections was terminated due to the rapid emergence of drug resistance during treatment. Nevertheless, epetraborole is in clinical development for nontuberculous mycobacteria (NTM) disease especially for Mycobacterium avium complex-related pulmonary disease (MAC-PD). DS86760016, an epetraborole analog, was further demonstrated to have an improved pharmacokinetic profile, lower plasma clearance, longer plasma half-life, and higher renal excretion than epetraborole in animal models. In this study, DS86760016 was found to be similarly active against M. abscessus in vitro, intracellularly, and in zebrafish infection models with a low mutation frequency. These results expand the diversity of druggable compounds as new benzoxaborole-based candidates for treating M. abscessus diseases.
Collapse
Affiliation(s)
- Thanh Quang Nguyen
- Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Bo Eun Heo
- Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Bui Thi Bich Hanh
- Division of Applied Life Science (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Seunghyeon Jeon
- Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Yujin Park
- Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Arunima Choudhary
- Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Sujin Lee
- Department of Applied Chemistry, Hanyang University, Ansan, Gyeonggi-do, Republic of Korea
- Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, Gyeonggi-do, Republic of Korea
| | - Tae Ho Kim
- Division of Applied Life Science (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| | - Cheol Moon
- Department of Clinical Laboratory Science, Semyung University, Jecheon, Republic of Korea
| | - Sun-Joon Min
- Department of Applied Chemistry, Hanyang University, Ansan, Gyeonggi-do, Republic of Korea
- Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, Gyeonggi-do, Republic of Korea
- Department of Chemical and Molecular Engineering, Hanyang University, Ansan, Gyeonggi-do, Republic of Korea
| | - Jichan Jang
- Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
- Division of Applied Life Science (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
| |
Collapse
|
3
|
Huang Y, Wang W, Huang Q, Wang Z, Xu Z, Tu C, Wan D, He M, Yang X, Xu H, Wang H, Zhao Y, Tu M, Zhou Q. Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia. Front Pharmacol 2022; 13:944965. [PMID: 36034783 PMCID: PMC9399346 DOI: 10.3389/fphar.2022.944965] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 06/07/2022] [Indexed: 11/13/2022] Open
Abstract
Objective: The aim of the research was to study the effect of azithromycin (AZM) in the treatment of MDR P. aeruginosa VAP combined with other antimicrobial therapies. Methods: The clinical outcomes were retrospectively collected and analyzed to elucidate the efficacy of different combinations involving azithromycin in the treatment of MDR-PA VAP. The minimal inhibitory concentration (MIC) of five drugs was measured by the agar dilution method against 27 isolates of MDR-PA, alone or in combination. Results: The incidence of VAP has increased approximately to 10.4% (961/9245) in 5 years and 18.4% (177/961) caused by P. aeruginosa ranking fourth. A total of 151 cases of MDR P. aeruginosa were included in the clinical retrospective study. Clinical efficacy results are as follows: meropenem + azithromycin (MEM + AZM) was 69.2% (9/13), cefoperazone/sulbactam + azithromycin (SCF + AZM) was 60% (6/10), and the combination of three drugs containing AZM was 69.2% (9/13). The curative effect of meropenem + amikacin (MEM + AMK) was better than that of the meropenem + levofloxacin (MEM + LEV) group, p = 0.029 (p < 0.05). The curative effect of cefoperazone/sulbactam + amikacin (SCF + AMK) was better than that of the cefoperazone/sulbactam + levofloxacin (SCF + LEV) group, p = 0.025 (p < 0.05). There was no significant difference between combinations of two or three drugs containing AZM, p > 0.05 (p = 0.806). From the MIC results, the AMK single drug was already very sensitive to the selected strains. When MEM or SCF was combined with AZM, the sensitivity of them to strains can be significantly increased. When combined with MEM and AZM, the MIC50 and MIC90 of MEM decreased to 1 and 2 ug/mL from 8 to 32 ug/mL. When combined with SCF + AZM, the MIC50 of SCF decreased to 16 ug/mL, and the curve shifted obviously. However, for the combination of SCF + LEV + AZM, MIC50 and MIC90 could not achieve substantive changes. From the FIC index results, the main actions of MEM + AZM were additive effects, accounting for 72%; for the combination of SCF + AZM, the additive effect was 40%. The combination of AMK or LEV with AZM mainly showed unrelated effects, and the combination of three drugs could not improve the positive correlation between LEV and AZM. Conclusion: AZM may increase the effect of MEM or SCF against MDR P. aeruginosa VAP. Based on MEM or SCF combined with AMK or AZM, we can achieve a good effect in the treatment of MDR P. aeruginosa VAP.
Collapse
Affiliation(s)
- Yuqin Huang
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Wenguo Wang
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Qiang Huang
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Zhengyan Wang
- Department of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Zhuanzhuan Xu
- Department of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Chaochao Tu
- Department of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Dongli Wan
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Miaobo He
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
| | - Xiaoyi Yang
- Department of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, China
| | - Huaqiang Xu
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
- *Correspondence: Huaqiang Xu, ; Hanqin Wang, ; Ying Zhao, ; Mingli Tu, ; Quan Zhou,
| | - Hanqin Wang
- Center for Translational Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
- *Correspondence: Huaqiang Xu, ; Hanqin Wang, ; Ying Zhao, ; Mingli Tu, ; Quan Zhou,
| | - Ying Zhao
- Department of Clinical Laboratory, Taihe Hospital, Hubei University of Medicine, Shiyan, China
- *Correspondence: Huaqiang Xu, ; Hanqin Wang, ; Ying Zhao, ; Mingli Tu, ; Quan Zhou,
| | - Mingli Tu
- Department of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
- *Correspondence: Huaqiang Xu, ; Hanqin Wang, ; Ying Zhao, ; Mingli Tu, ; Quan Zhou,
| | - Quan Zhou
- Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, China
- *Correspondence: Huaqiang Xu, ; Hanqin Wang, ; Ying Zhao, ; Mingli Tu, ; Quan Zhou,
| |
Collapse
|
4
|
Das BC, Adil Shareef M, Das S, Nandwana NK, Das Y, Saito M, Weiss LM. Boron-Containing heterocycles as promising pharmacological agents. Bioorg Med Chem 2022; 63:116748. [PMID: 35453036 DOI: 10.1016/j.bmc.2022.116748] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 03/16/2022] [Accepted: 04/08/2022] [Indexed: 11/28/2022]
Abstract
The incorporation of the "magic" boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been shown to form various bonds with their biological targets. Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, and several other boron-containing compounds are in clinical trials. Boron-based heterocycles have an incredible potential in the ongoing quest for new therapeutic agents owing to their plethora of biological activities and useful pharmacokinetic profiles. The present perspective is intended to review the pharmacological applications of boron-based heterocycles that have been published. We have classified these compounds into groups exhibiting shared pharmacological activities and discussed their corresponding biological targets focusing mainly on the most potent therapeutic compounds.
Collapse
Affiliation(s)
- Bhaskar C Das
- Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA; Department of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
| | - Mohammed Adil Shareef
- Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
| | - Sasmita Das
- Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
| | - Nitesh K Nandwana
- Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
| | - Yogarupa Das
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
| | - Mariko Saito
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
| | - Louis M Weiss
- Department of Medicine, Division of Infectious Diseases and Department of Pathology Division of Parasitology and Tropical Medicine, Albert Einstein College of Medicine, Bronx NY-10461, USA
| |
Collapse
|
5
|
Kumar M, Mathur T, Barman TK, Chaira T, Kumar R, Joshi V, Pandya M, Sharma L, Fujii K, Bandgar M, Jadhav B, Bambal R, Upadhyay D, Masuda N, Verma AK, Bhatnagar PK. Novel FtsZ inhibitor with potent activity against Staphylococcus aureus. J Antimicrob Chemother 2021; 76:2867-2874. [PMID: 34383913 DOI: 10.1093/jac/dkab270] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Accepted: 06/29/2021] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES FtsZ is an essential bacterial protein and an unexplored target for the development of antibacterial drugs. The development of a novel inhibitor targeting FtsZ offers a potential opportunity to combat drug resistance. DS01750413, a new derivative of PC190723, is a novel FtsZ inhibitor with improved in vitro and in vivo activity. The objective of this study was to investigate the efficacy of DS01750413 against Staphylococcus spp., including MRSA, in in vitro and in vivo models. METHODS In vitro activities of DS01750413 and standard-of-care antibiotics were evaluated against clinical isolates of Gram-positive pathogens. The in vivo efficacy was evaluated in a murine systemic infection model caused by MRSA. RESULTS DS01750413 showed potent in vitro activity against MRSA clinical isolates with MIC ranges of 0.5-1 mg/L and also demonstrated concentration-dependent bactericidal killing. In the murine bacteraemia infection model of MRSA, treatment with DS01750413 resulted in prolonged survival of animals compared with placebo-treated animals and exhibited a significant reduction in the bacterial load in liver, spleen, lungs and kidneys. CONCLUSIONS DS01750413 showed encouraging in vitro and in vivo activity against MRSA. As a novel chemical class, DS01750413 has the potential to become clinically viable antibiotics to address the drug resistance problem by its unique novel targeting mechanism of action.
Collapse
Affiliation(s)
- Manoj Kumar
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Tarun Mathur
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Tarani Kanta Barman
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Tridib Chaira
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Ram Kumar
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Vattan Joshi
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Manisha Pandya
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Lalima Sharma
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Kunihiko Fujii
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Mahadev Bandgar
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Balasaheb Jadhav
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Ramesh Bambal
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Dilip Upadhyay
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Nobuhisa Masuda
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Ashwani Kumar Verma
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| | - Pradip Kumar Bhatnagar
- Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India
| |
Collapse
|
6
|
Kumar M, Rao M, Mathur T, Barman TK, Joshi V, Chaira T, Singhal S, Pandya M, Al Khodor S, Upadhyay DJ, Masuda N. Azithromycin Exhibits Activity Against Pseudomonas aeruginosa in Chronic Rat Lung Infection Model. Front Microbiol 2021; 12:603151. [PMID: 33967970 PMCID: PMC8102702 DOI: 10.3389/fmicb.2021.603151] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Accepted: 03/15/2021] [Indexed: 12/19/2022] Open
Abstract
Pseudomonas aeruginosa forms biofilms in the lungs of chronically infected cystic fibrosis patients, which are tolerant to both the treatment of antibiotics and the host immune system. Normally, antibiotics are less effective against bacteria growing in biofilms; azithromycin has shown a potent efficacy in cystic fibrosis patients chronically infected with P. aeruginosa and improved their lung function. The present study was conducted to evaluate the effect of azithromycin on P. aeruginosa biofilm. We show that azithromycin exhibited a potent activity against P. aeruginosa biofilm, and microscopic observation revealed that azithromycin substantially inhibited the formation of solid surface biofilms. Interestingly, we observed that azithromycin restricted P. aeruginosa biofilm formation by inhibiting the expression of pel genes, which has been previously shown to play an essential role in bacterial attachment to solid-surface biofilm. In a rat model of chronic P. aeruginosa lung infection, we show that azithromycin treatment resulted in the suppression of quorum sensing-regulated virulence factors, significantly improving the clearance of P. aeruginosa biofilms compared to that in the placebo control. We conclude that azithromycin attenuates P. aeruginosa biofilm formation, impairs its ability to produce extracellular biofilm matrix, and increases its sensitivity to the immune system, which may explain the clinical efficacy of azithromycin in cystic fibrosis patients.
Collapse
Affiliation(s)
- Manoj Kumar
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India.,Research Department, Sidra Medicine, Doha, Qatar
| | - Madhvi Rao
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Tarun Mathur
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Tarani Kanta Barman
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Vattan Joshi
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Tridib Chaira
- Department of Pharmacokinetics and Metabolism, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Smita Singhal
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Manisha Pandya
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | | | - Dilip J Upadhyay
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| | - Nobuhisa Masuda
- Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, India
| |
Collapse
|
7
|
Tevyashova AN, Chudinov MV. Progress in the medicinal chemistry of organoboron compounds. RUSSIAN CHEMICAL REVIEWS 2021. [DOI: 10.1070/rcr4977] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The review aims to draw attention to the latest advances in the organoboron chemistry and therapeutic use of organoboron compounds. The synthetic strategies towards boron-containing compounds with proven in vitro and/or in vivo biological activities, including derivatives of boronic acids, benzoxaboroles, benzoxaborines and benzodiazaborines, are summarized. Approaches to the synthesis of hybrid structures containing an organoboron moiety as one of the pharmacophores are considered, and the effect of this modification on the pharmacological activity of the initial molecules is analyzed. On the basis of analysis of the published data, the most promising areas of research in the field of organoboron compounds are identified, including the latest methods of synthesis, modification and design of effective therapeutic agents.
The bibliography includes 246 references.
Collapse
|